Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.
Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.